IceCure Medical (NASDAQ:ICCM) Upgraded by Wall Street Zen to “Hold” Rating

Wall Street Zen upgraded shares of IceCure Medical (NASDAQ:ICCM) from a sell rating to a hold rating in a research note issued to investors on Saturday morning,Wall Street Zen reports.

Other equities research analysts also recently issued research reports about the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of IceCure Medical in a research note on Friday, July 17th. Maxim Group reduced their price target on shares of IceCure Medical from $90.00 to $30.00 and set a “buy” rating on the stock in a research report on Thursday, May 14th. Finally, Zacks Research cut shares of IceCure Medical from a “hold” rating to a “strong sell” rating in a research report on Friday, August 14th. Three analysts have rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $52.50.

IceCure Medical Trading Up 1.4%

IceCure Medical stock opened at $2.23 on Friday. The firm has a market capitalization of $7.64 million, a P/E ratio of -0.26 and a beta of 0.45. IceCure Medical has a 1 year low of $2.12 and a 1 year high of $42.00. The business has a 50-day moving average of $3.24 and a 200-day moving average of $8.14.

IceCure Medical (NASDAQ:ICCM) last announced its quarterly earnings results on Tuesday, June 30th. The company reported ($1.60) EPS for the quarter. The company had revenue of $0.91 million during the quarter. IceCure Medical had a negative net margin of 427.67% and a negative return on equity of 174.26%. Research analysts anticipate that IceCure Medical will post -4.61 EPS for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in IceCure Medical stock. Virtu Financial LLC acquired a new position in shares of IceCure Medical Ltd. (NASDAQ:ICCM) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 64,524 shares of the company’s stock, valued at approximately $39,000. Virtu Financial LLC owned 0.09% of IceCure Medical as of its most recent SEC filing. Institutional investors and hedge funds own 0.62% of the company’s stock.

IceCure Medical Company Profile

IceCure Medical Ltd. (NASDAQ: ICCM) is a clinical-stage medical device company specializing in the development and commercialization of proprietary cryoablation systems for the treatment of tumors and other pathological tissues. The company’s core technology employs a unique liquid-nitrogen-based platform to deliver rapid cooling through fine-gauge cryoprobes, enabling precise and minimally invasive tissue ablation under imaging guidance. IceCure’s lead product, ProSense, is designed to offer a single-probe approach that can be deployed in an outpatient setting, reducing procedure time and patient recovery periods.

Originally founded in Israel, IceCure Medical obtained its first CE mark for the treatment of benign breast tumors and fibroadenomas in 2017.